Robert Langreth
-
Psychedelic Drug Maker Cuts 75% Of Staff After FDA Rejects MDMA
The company said it will leave only a small team focussed on reversing the Food and Drug Administration’s decision.
-
Ozempic Linked To Rare Cases Of Vision Loss In Harvard Study
Patients who took Ozempic and Wegovy were more than seven times more likely to be diagnosed with a stroke-like eye condition than those taking other classes of drugs for obesity, according to the study of patient records.
-
Moderna Reports $3.6 Billion Loss On Covid Supply Writedowns
Moderna Inc. reported a larger-than-expected loss in the third quarter after registering a $3.1 billion charge to write down excess Covid shots and reduce its manufacturing footprint as the vaccine maker prepares for a post-pandemic era.
-
FDA Tests New Power to Pull Some Fast-Tracked Drugs Off Market
Its first target is a cancer treatment from Oncopeptides given accelerated approval in 2021, which has since faced a study questioning its effectiveness.
-
Eli Lilly Drug Slows Alzheimer’s Disease, Study Finds
The drug, donanemab, slowed the disease by 35% over a year and a half in a trial of 1,182 patients with early-stage Alzheimer’s, Lilly said.
-
Good Luck Paying for Those $10,000 Obesity Drugs Everyone's Talking About
Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.
-
Good Luck Paying for Those $10,000 Obesity Drugs Everyone's Talking About
Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.
-
Pfizer to Test Second Paxlovid Course in Patients With Covid Rebound
Pfizer Inc. was ordered by US regulators to test the effects of an additional course of Paxlovid among people who experience a rebound in Covid-19 after treatment, putting the drug through further study as reports of the mysterious phenomenon continue to mount.
-
Juul Continues Selling Vaping Products After FDA Stays Ban
Shares of Altria Group Inc., the Marlboro cigarette maker fell 1.2% as of 1 p.m. in New York.
-
Juul Continues Selling Vaping Products After FDA Stays Ban
Shares of Altria Group Inc., the Marlboro cigarette maker fell 1.2% as of 1 p.m. in New York.
-
New Drug Prices Soar To $180,000 A Year On 20% Annual Inflation
The median launch price of a new drug in the US soared from $2,115 in 2008 to $180,007 in 2021.
-
Pfizer’s Advice on Retaking Covid Drug Contradicted by FDA
FDA Contradicts Pfizer’s Advice on Second Course of Covid Drug
-
Pfizer Says Patients Who Relapse After Covid Pill Can Repeat
Pfizer Says Patients Who Relapse After Covid Pill Can Take More
-
Biogen Walks Away From Alzheimer’s Flop With CEO Set to Depart
Biogen Walks Away From Alzheimer’s Flop With CEO Set to Depart
-
Covid Vaccines for Kids Seen Getting FDA Panel Review in June
Covid Vaccines for Kids Seen Getting FDA Panel Review in June
